title: [Medicinal chemistry and pharmacology focused on cannabidiol, a major component of the fiber-type cannabis].
abstract: Considerable attention has focused on cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, and it has been reported to possess diverse biological activities. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule, cannabidiolic acid (CBDA), several studies have investigated whether CBDA itself is biologically active. In the present report, the author summarizes findings indicating that; 1) CBDA is a selective cyclooxygenase-2 (COX-2) inhibitor, and ii) CBDA possesses an anti-migrative potential for highly invasive cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. Further, the author introduces recent findings on the medicinal chemistry and pharmacology of the CBD derivative, CBD-2',6'-dimethyl ether (CBDD), that exhibits inhibitory activity toward 15-lipoxygenase (15-LOX), an enzyme responsible for the production of oxidized low-density lipoprotein (LDL). These studies establish CBD as both an important experimental tool and as a lead compound for pharmaceutical development. In this review, the author further discusses the potential uses of CBD and its derivatives in future medicines.
authors.affiliation: Department of Molecular Biology, Daiichi University of Pharmacy.
authors.forename: Shuso
authors.initials: S
authors.lastname: Takeda
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology; D002185:Cannabidiol / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology*; D002186:Cannabinoids / Q000737:chemistry; D002188:Cannabis / Q000737:chemistry*; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D002626:Chemistry, Pharmaceutical; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D052246:Cyclooxygenase 2 Inhibitors; D003653:Decarboxylation; D055808:Drug Discovery; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D008517:Phytotherapy; D020742:rhoA GTP-Binding Protein / Q000378:metabolism
chemical_list: D002186:Cannabinoids; D052246:Cyclooxygenase 2 Inhibitors; D008077:Lipoproteins, LDL; D016859:Lipoxygenase Inhibitors; C099252:oxidized low density lipoprotein; C065844:cannabidiol dimethyl ether; D002185:Cannabidiol; D017868:Cyclic AMP-Dependent Protein Kinases; D020742:rhoA GTP-Binding Protein; C006884:cannabidiolic acid